Vascular occlusive events and hemorrhage in the brain affect thousands of lives across the globe every day. Thrombosis and hemostasis impact outcome after cerebrovascular disease, and its prevention and treatment include manipulation of systemic coagulation factors. The brain also has its own unique system for regulation of hemostasis.[1] Local thrombin generation in the brain affects the prognosis in epileptic seizures and multiple sclerosis,[2] while tissue plasminogen activator (tPa) affects blood–brain barrier permeability and is involved in Alzheimer's disease pathology.[3] This issue of Seminars of Thrombosis and Hemostasis will, in three parts, shed light on mechanisms and potential treatment targets in vascular occlusive events, in intracerebral and subarachnoid hemorrhage, and finally in the role of platelets and endogenous tPa in Alzheimer's and Parkinson's diseases.
2
Stein ES BS,
Gofrit SG,
Altman K,
Weinberg N,
Maggio N.
Neurocoagulation from a mechanistic point of view in the central nervous system. Semin Thromb Hemost 2022; 48 (03) 277-287
3
Stevenson TK,
Moore SJ,
Murphy GG,
Lawrence DA.
Tissue plasminogen activator in central nervous system physiology and pathology: from synaptic plasticity to Alzheimer's disease. Semin Thromb Hemost 2022; 48 (03) 288-300
7
Panagopoulos D,
Karydakis P,
Noutsos G,
Themistocleous M.
Venous thromboembolism risk and thromboprophylaxis in pediatric neurosurgery and spinal injury: current trends and literature review. Semin Thromb Hemost 2022; 48 (03) 318-322
8
Winther-Larsen A,
Sandfeld-Paulsen B,
Hvas AM.
New insights in coagulation and fibrinolysis in patients with primary brain cancer: a systematic review. Semin Thromb Hemost 2022; 48 (03) 323-337
13
Page MJ,
Pretorius E.
Platelet behavior contributes to neuropathologies: a focus on Alzheimer's and Parkinson's disease. Semin Thromb Hemost 2022; 48 (03) 382-404